BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

469 related articles for article (PubMed ID: 10494328)

  • 1. [Selective estrogen-receptor modulators (SERM's) in postmenopausal women].
    Hart W; Netelenbos JC
    Ned Tijdschr Geneeskd; 1999 Aug; 143(35):1771-6. PubMed ID: 10494328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective estrogen receptor modulators: a new category of compounds to extend postmenopausal women's health.
    Goldstein SR
    Int J Fertil Womens Med; 1999; 44(5):221-6. PubMed ID: 10569450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical experience with raloxifene].
    Szúcs J; Pávó I; Jurida N
    Orv Hetil; 2000 Jan; 141(5):237-40. PubMed ID: 10697982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effects of raloxifene on other organs without bone: uterus].
    Nozaki M
    Clin Calcium; 2004 Oct; 14(10):55-60. PubMed ID: 15577132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Selective estrogen receptor modulators (SERMs) in the practice].
    Nagykálnai T
    Magy Onkol; 2002; 46(2):165-75. PubMed ID: 12202896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women.
    Lee WL; Chao HT; Cheng MH; Wang PH
    Maturitas; 2008 Jun; 60(2):92-107. PubMed ID: 18534794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Additional effect of SERM: mammary gland].
    Kurebayashi J
    Clin Calcium; 2004 Oct; 14(10):47-51. PubMed ID: 15577131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Raloxifene, tamoxifen and vascular tone.
    Leung FP; Tsang SY; Wong CM; Yung LM; Chan YC; Leung HS; Yao X; Huang Y
    Clin Exp Pharmacol Physiol; 2007 Aug; 34(8):809-13. PubMed ID: 17600563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tamoxifen, raloxifene and the prevention of breast cancer.
    Bentrem DJ; Craig Jordan V
    Minerva Endocrinol; 2002 Jun; 27(2):127-39. PubMed ID: 11961504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Which is the better choice, estrogen or SERMs in postmenopausal women?].
    Shintani M
    Clin Calcium; 2004 Oct; 14(10):105-10. PubMed ID: 15577140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Selective estrogen receptors modulators (SERMs): biochemistry, pharmacology, and clinical use in gynecology].
    Terán Dávila J; Teppa Garrán AD
    Ginecol Obstet Mex; 2005 Aug; 73(8):424-35. PubMed ID: 16304968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Raloxifene: a selective modulator of estrogen receptors].
    van den Brûle FA; Kalbus MF; Gaspard UJ
    J Gynecol Obstet Biol Reprod (Paris); 1999 Dec; 28(8):788-99. PubMed ID: 10635481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Lasofoxifene, a next generation estrogen receptor modulator: preclinical studies].
    Maeda T; Ke HZ; Simmons H; Thompson D
    Clin Calcium; 2004 Oct; 14(10):85-93. PubMed ID: 15577137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Selective estrogen receptor modulators (SERM): new substances for hormone replacement therapy].
    Burckhardt P
    Schweiz Med Wochenschr; 1999 Dec; 129(49):1926-30. PubMed ID: 10635085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of SERMs for treatment in postmenopausal women.
    Pinkerton JV; Thomas S
    J Steroid Biochem Mol Biol; 2014 Jul; 142():142-54. PubMed ID: 24373794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Selective estrogen receptor modulators (SERMs)].
    Matsumoto T
    Clin Calcium; 2006 Sep; 16(9):1520-25. PubMed ID: 16951478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years.
    Jolly EE; Bjarnason NH; Neven P; Plouffe L; Johnston CC; Watts SD; Arnaud CD; Mason TM; Crans G; Akers R; Draper MW
    Menopause; 2003; 10(4):337-44. PubMed ID: 12851517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Raloxifene for the treatment and prevention of breast cancer?
    Pappas SG; Jordan VC
    Expert Rev Anticancer Ther; 2001 Oct; 1(3):334-40. PubMed ID: 12113100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer.
    Ganz PA; Land SR
    Menopause; 2008; 15(4 Suppl):797-803. PubMed ID: 18596601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Raloxifene: bone and cardiovascular effects.
    Francucci CM; Romagni P; Boscaro M
    J Endocrinol Invest; 2005; 28(10 Suppl):85-9. PubMed ID: 16550730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.